Phase III TAISHAN-302 Trial Shows Tam-Peli Significantly Improves Survival in Relapsed Small-Cell Lung Cancer
Phase 3positiveTam-PelitopotecanPositive
AI Analysis
Summary
Phase III TAISHAN-302 trial demonstrated that Tam-Peli (tambotatug pelitecan), an anti-B7-H3 antibody-drug conjugate, reduced death risk by 54% compared to topotecan in relapsed small-cell lung cancer patients and improved progression-free survival and response rates.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Tam-Peli reduced risk of death by 54% versus topotecan, improved progression-free survival and response rates
Importance:8/10
Sentiment:
0.90
Phase 3 dataoncologyantibody-drug conjugatesmall-cell lung cancersurvival benefit
Read the original article
Published by PR Newswire Biotech on September 13, 2026 12:57 PM